How to Build Competitive Intelligence from FDA 510(k) Public Data

Your competitors' regulatory submissions are public documents. The 510(k) summary, the product code, the predicate they chose, the clearance date, the decision — all of it is freely available in FDA's CDRH database. Most companies check it occasionally. Very few use it systematically as a competitive intelligence source.

Here's what you can learn from public 510(k) data, and how to extract it.

What 510(k) Data Tells You

Clearance Velocity

How fast is your competitor getting new devices cleared? A company clearing 5-6 AI devices per year is building a clearance moat — each new clearance is another predicate they can use internally and another indication they've established regulatory precedent in. A company that cleared once three years ago may have regulatory challenges you don't know about.

Predicate Strategy

Which predicate did they use? The predicate choice reveals how a company is positioning its technology. A competitor using a narrow predicate is making a precise claim; one using a broad predicate is positioning for expansion. If they're citing your device as a predicate, that's both a compliment and a competitive signal.

Product Code Expansion

Is your competitor clearing devices in new product codes? A radiology AI company that just cleared a cardiology device has expanded its regulatory footprint — and probably has commercial intentions to match.

PCCP Status

Which competitors have approved PCCPs? Companies with PCCPs can iterate their algorithms faster than companies without them. A competitor with a broad PCCP is building a regulatory advantage that compounds over time as they improve their algorithm without needing new submissions for each improvement.

Submission Type

Traditional 510(k) vs Special 510(k) vs De Novo tells you something about the novelty and complexity of what your competitor is doing. A De Novo means they're pioneering new territory. A Special 510(k) for an algorithm update suggests their pipeline is mature and their regulatory process is efficient.

What 510(k) Summaries Reveal

The 510(k) summary document — publicly available for most cleared devices — contains more detail than most people realize:

• The device description, including algorithm type and architecture (at a high level)
• The intended use and indications for use — the exact regulatory claims
• The substantial equivalence comparison — what they argued makes them equivalent to their predicate
• Performance data — sensitivity, specificity, AUC, or other metrics at the level disclosed
• Labeling information — what they're allowed to say in marketing

Reading competitor 510(k) summaries systematically tells you what performance benchmarks FDA has accepted in your category, what claims FDA has cleared, and what arguments for substantial equivalence have worked.

Building a Systematic Competitive Database

The manual approach — searching CDRH by company name or product code — is time-consuming and easy to miss. A systematic approach requires:

First, define your product code universe. Identify all product codes relevant to your indication. Monitor all new clearances in those codes, not just clearances from known competitors.

Second, set up monitoring. New 510(k) clearances are published daily. Without automated monitoring, you'll miss them. By the time you find a competitor's clearance, they've already started commercial activities based on it.

Third, track PCCP grants. When a competitor receives a PCCP approval, it's not always obvious from the clearance record. PCCP-enabled clearances are identifiable but require specific searches.

Fourth, connect clearances to enforcement. A competitor with multiple warning letters in your space is either a sign of regulatory risk in the category or an indication that FDA is paying close attention to compliance — both of which affect your strategy.

The Intelligence No One Collects

The most valuable competitive intelligence from FDA data is the trend data — not what any single competitor did, but what patterns emerge across the whole category:

• Is clearance velocity in your indication increasing or decreasing? (Increasing = more competition entering)
• Are review times getting longer? (Signals FDA scrutiny is increasing)
• Are MAUDE reports increasing for devices in your category? (Signals real-world performance issues that could affect your regulatory pathway)
• Are enforcement actions concentrated in specific companies or distributed across the category? (Concentrated = competitor-specific issue; distributed = systemic regulatory concern)

This trend analysis is what separates companies that use FDA data as a lookup tool from those that use it as a strategic intelligence source.